

doi: 10.1093/qjmed/hcab231 Letter to Editor

## LETTER TO EDITOR

## Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination

## A. Ioannou 📵

From the Department of Cardiology, Royal Free Hospital, Royal Free NHS Foundation Trust, Pond Street, London NW3 2QG, UK. email: adam.ioannou@nhs.net

Dear Editor, I read with interest the case series by Lee *et al.*<sup>1</sup> in which the authors describe three cases of cardiac complications following Pfizer-BioNTech COVID-19 vaccination. In Case 3, they describe a 73-year-old woman who presented with shortness of breath and palpitations 2h after receiving her first dose of the vaccine. Her electrocardiogram did not demonstrate any signs of ischaemia but troponin I peaked at 180 ng/l 6h after presenting to the Emergency Department. Transthoracic echocardiogram showed a normal left ventricular ejection fraction of 60% with no regional wall motion abnormalities.

She underwent an invasive coronary angiogram that demonstrated a moderate lesion in the left anterior descending artery. This was confirmed to be non-flow limiting with a fractional flow reserve of 0.83. The remaining coronary arteries were also unobstructed. The authors concluded that this patient had a myocardial infarction with non-obstructive coronary artery disease.

Vaccine-induced myocarditis has been well described in the literature and although uncommon is an established side effect of the Pfizer-BioNTech COVID-19 vaccine.<sup>2–5</sup> Therefore, in a patient with a troponin rise and unobstructed coronary arteries, a diagnosis of myocarditis should be considered as a possible diagnosis. I would suggest in such cases cardiac magnetic resonance imaging should be utilized to assess for myocardial

inflammation, oedema and fibrosis; and also confirm the underlying aetiology of the troponin rise.

Conflict of interest. None declared.

## References

- Lee E, Chew NW, Ng P, Yeo TJ. A spectrum of cardiac manifestations post Pfizer-BioNTech COVID-19 vaccination. QJM 2021; doi:10.1093/qjmed/hcab177.
- 2. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. *JAMA Cardiol* 2021; e212833.
- Abu Mouch S, Roguin A, Hellou E, Ishai A, Shoshan U, Mahamid L, et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine 2021; 39:3790–3.
- 4. Lazaros G, Klein AL, Hatziantoniou S, Tsioufis C, Tsakris A, Anastassopoulou C. The novel platform of mRNA COVID-19 vaccines and myocarditis: clues into the potential underlying mechanism. Vaccine 2021; 39:4925–7.
- 5. Nassar M, Nso N, Gonzalez C, Lakhdar S, Alshamam M, Elshafey M, et al. COVID-19 vaccine-induced myocarditis: case report with literature review. Diabetes Metab Syndr 2021; 15: 102205.